Pioglitazone might prevent the progression of slowly progressive type 1 diabetes

Yoshinaga Kawano, Junichiro Irie, Hiroshi Nakatani, Satoru Yamada

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (ΣC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.

Original languageEnglish
Pages (from-to)1037-1039
Number of pages3
JournalInternal Medicine
Volume48
Issue number12
DOIs
Publication statusPublished - 2009

Fingerprint

pioglitazone
Type 1 Diabetes Mellitus
Insulin
C-Peptide
Hypoglycemic Agents
Anti-Idiotypic Antibodies
Injections

Keywords

  • Anti-GAD antibody
  • Pioglitazone
  • PPAR-γ
  • Slowly progressive type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. / Kawano, Yoshinaga; Irie, Junichiro; Nakatani, Hiroshi; Yamada, Satoru.

In: Internal Medicine, Vol. 48, No. 12, 2009, p. 1037-1039.

Research output: Contribution to journalArticle

Kawano, Yoshinaga ; Irie, Junichiro ; Nakatani, Hiroshi ; Yamada, Satoru. / Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. In: Internal Medicine. 2009 ; Vol. 48, No. 12. pp. 1037-1039.
@article{787acfb82e27483ea329f6637298c5b0,
title = "Pioglitazone might prevent the progression of slowly progressive type 1 diabetes",
abstract = "Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (ΣC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.",
keywords = "Anti-GAD antibody, Pioglitazone, PPAR-γ, Slowly progressive type 1 diabetes",
author = "Yoshinaga Kawano and Junichiro Irie and Hiroshi Nakatani and Satoru Yamada",
year = "2009",
doi = "10.2169/internalmedicine.48.1990",
language = "English",
volume = "48",
pages = "1037--1039",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "12",

}

TY - JOUR

T1 - Pioglitazone might prevent the progression of slowly progressive type 1 diabetes

AU - Kawano, Yoshinaga

AU - Irie, Junichiro

AU - Nakatani, Hiroshi

AU - Yamada, Satoru

PY - 2009

Y1 - 2009

N2 - Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (ΣC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.

AB - Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (ΣC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.

KW - Anti-GAD antibody

KW - Pioglitazone

KW - PPAR-γ

KW - Slowly progressive type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=67650078962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650078962&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.48.1990

DO - 10.2169/internalmedicine.48.1990

M3 - Article

VL - 48

SP - 1037

EP - 1039

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 12

ER -